Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials
Alimentary Pharmacology and Therapeutics, 05/25/2012Lichtenstein GR et al.
Mesalazine granules 1.5 g once–daily is effective for maintenance of remission in ulcerative colitis (UC) patients who switch from other 5–aminosalicylic acid (5–ASA) formulations.
Data from two independent multicenter, randomised, double–blind, placebo–controlled, 6–month trials evaluating patients with UC in remission were combined for analysis of a subpopulation of patients who switched from other 5–ASA formulations to MG 1.5 g or placebo upon randomisation.
The primary endpoint was the percentage of patients who remained relapse–free at Month 6 or end of treatment.
Relapse was defined as a Sutherland Disease Activity Index (SDAI) rectal bleeding score ≥1 and mucosal appearance score ≥2, a UC flare or medication used to treat a UC flare.
Of the 487 patients who received 5–ASA maintenance therapy at enrolment, 322 were in the MG group and 165 were in the placebo group.
The percentage of patients who remained relapse–free (based on Sutherland Disease Activity Index scores) after 6 months was significantly higher with MG than placebo (78.3% vs. 58.8%, P < 0.001).
Rectal bleeding, stool frequency and the physician's rating of disease activity remained unchanged after 6 months in a higher percentage of patients using MG compared with those on placebo (P < 0.004 for each endpoint).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.